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1. Introduction 
Cyclosporin was isolated in 1970, by Jean François Borel at Sandoz Laboratories (Basel, 
Switzerland), from the soil fungus Tolypocladium inflatum (Borel et al., 1995; Amor et al., 
2010). The compound was initially identified as a possible antifungal agent, but it was 
subsequently shown to have limited antifungal activity. However, in 1976, the drug 
demonstrated potent immunosuppressive properties, and two years later, it was 
successfully shown to prevent renal allograft rejection in renal transplant recipients. A year 
later, a pilot study showed that cyclosporin improved psoriasis in patients treated for  
rheumatoid and psoriatic arthritis. Ultimately, in the early 1990s, cyclosporin was approved 
in Europe for the treatment of psoriasis and atopic dermatitis. In 1997, the United States 
Food and Drug Administration approved a microemulsion formulation of cyclosporin 
(Neoral®; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA) for the treatment 
of severe psoriasis in adults. Worldwide, cyclosporin has been used extensively in various 
dermatological disorders: e.g. pyoderma gangrenosum, and refractory chronic idiopathic 
urticaria (Amor et al., 2010; Vena et al., 2006). 
Despite such a distinguished clinical history, some dermatologists have been rather hesitant 
to use cyclosporin because of concerns about possible adverse effects (Amor et al., 2010; 
Ryan et al., 2010); however a ‘framework’ of detailed clinical data now widely supports the 
effective and safe use of cyclosporin within dermatologists’ prescribing guidelines, 
especially when the drug is used as a ‘rescue’, or intermittent short-term treatment for 
severe psoriasis, psoriatic arthritis, or atopic dermatitis (Amor et al., 2010). 
Another particularly pertinent consideration is that ‘conventional’ and generic (including 
generic microemulsion) formulations of cyclosporin are associated with marked intra- and 
interindividual variability in absorption, thus creating the potential for subtherapeutic 
dosing at one extreme and toxicity at the other (Colombo & Egan, 2010; Ryan et al., 2010). 
For this reason, generic formulations have not yet been approved in several countries. 
Conversely, the microemulsion Neoral® preparation is associated with low intra- and 
interpatient variability in cyclosporin absorption and with a consistent dose-exposure 
relationship. This highlights the importance of prescribing the most clinically appropriate 
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cyclosporin preparation, and of avoiding any confusion between the various cyclosporin 
formulations available (Colombo & Egan, 2010). Indeed, a Canadian survey reported that up 
to 20% of new cyclosporin recipients may be given a cyclosporin formulation different from 
that actually prescribed (Davies & Gupta 2000). 
This chapter will review the following with respect to psoriasis treatment: 
 The mechanism of cyclosporin action 
 The pharmacokinetic properties of cyclosporin 
 The efficacy of cyclosporin in well-designed, randomised controlled trials, with 
important economic information from certain key clinical trials 
 The role of cyclosporin in current combination therapy 
 Side effects of the compound. 
2. Mechanism of action 
Cyclosporin, an 11-amino acid, cyclic polypeptide produced from the fungal species 
Beauveria nivea, is a calcineurin inhibitor that acts selectively on T cells (Amor et al., 2010). 
Cyclosporin binds to the intracellular immunophilin cyclophilin to form a complex, which 
then binds to and inhibits the enzymatic activity of calcineurin phosphatase, a serine- 
  
Fig. 1. Mechanism of cyclosporine action. Cyclosporine (CsA) binds to cyclophylin (CpN), 
forming a complex that  binds and blocks the function of the enzyme calcineurin (CaN). As a 
result, CaN fails to dephosphorylate the cytoplasmic component of the nuclear factor of 
activated T cells (NF-ATc), and the transport of NF-ATc to the nucleus and the binding of 
NF-ATc to the nuclear component of the nuclear factor of activated T cells (NF-ATn). The 
NF-ATc–NF-ATn complex binds to the promoter of the interleukin 2 (IL-2) gene and 
initiates IL-2 production. Consequently, T cells do not produce IL-2, which is necessary for 
full T-cell activation.(Modified from Stepkowski, S.M. 2000) 
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threonine phosphatase that depends on calcium and calmodulin for activity (Amor et al., 
2010; Giese et al., 2004; Stepkowski 2000). Consequently, calcineurin cannot 
dephosphorylate an important transcription factor: the cytoplasmic component of nuclear 
factor of activated T cells (NF-ATc) [Fig.1]. Transport of NF-ATc to the cell nucleus, and 
binding of NF-ATc to the promoter region of the IL-2 gene nuclear component of NF-AT 
(NF-ATn), is therefore blocked and T cells can no longer produce IL-2, a cytokine required 
for complete activation of the T-cell pathway, granulocyte-macrophage colony-stimulating 
factor, and interferon-γ production (Amor et al., 2010; Giese et al., 2004). The consequences 
of cyclosporin action include (Amor et al., 2010): 
 Depletion of lymphocytes and macrophages in the epidermis and dermis 
 Downregulation of cellular adhesion molecule expression in the dermal capillary 
endothelium 
 Restricted activation of antigen-presenting cells, natural killer cells, and T cells 
 Inhibition of keratinocyte hyperproliferation 
 Restricted release of histamine from mast cells. 
3. Pharmacokinetic properties 
Cyclosporin is a lipophilic molecule that is poorly absorbed from ‘conventional’ orally 
administered formulations, with major variations in intra- and inter-patient bioavailability 
(Ryan et al., 2010). A microemulsion preparation (Neoral®; Novartis, East Hanover, New 
Jersey, USA) was therefore developed with greater hydrophilicity, and higher 
bioavailability (Colombo & Egan, 2010). There is marked variability among conventional 
formulations, and for the microemulsion vs conventional formulations : oral forms of 
cyclosporin are generally not bioequivalent,(Colombo & Egan, 2010) except for Neoral® soft 
gelatin capsules and Neoral® oral solution, which are bioequivalent (Novartis 
Pharmaceuticals UK Ltd 2011). Conventional and generic (including generic microemulsion) 
formulations of cyclosporin are characterised by considerable intra- and inter-individual 
variability in absorption (Colombo & Egan, 2010; Ryan et al., 2010). By contrast, there is low 
variability in cyclosporin absorption from the microemulsion Neoral® preparation, which 
provides a consistent dose-exposure relationship (Colombo & Egan, 2010). 
Peak plasma cyclosporin concentrations are attained 1–6 hours after administration of a 
conventional soft gelatin capsule formulation (Sandimmune®; Novartis Pharmaceuticals 
Corporation, East Hanover, New Jersey, USA), but 1.5–2.0 hours after oral administration of 
the microemulsion formulation (Neoral®) (Novartis Pharmaceuticals Corporation 2009; 
Novartis Pharmaceuticals UK Ltd 2011). Mean peak plasma cyclosporin concentration (Cmax) 
after administration of the microemulsion versus conventional preparation is 40–106% 
greater, and mean area under the plasma concentration versus time curve (AUC) is 20–50% 
greater (Novartis Pharmaceuticals Corporation 2009; Novartis Pharmaceuticals UK Ltd 
2011). After 4 weeks’ administration of Neoral® at a mean dosage of 2.48 mg/kg/day in 18 
patients with psoriasis, mean Cmax was 655 ng/mL and mean AUC was 2324 
ngh/mL.(Novartis Pharmaceuticals Corporation 2009) 
Cyclosporin is extensively distributed throughout the body, in plasma (33–47% of an 
administered dose), lymphocytes (4–9%), granulocytes (5–12%), and erythrocytes (41–58%) 
(Novartis Pharmaceuticals Corporation 2009). In plasma, cyclosporin is extensively bound 
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to proteins (~90%), primarily lipoproteins,(Novartis Pharmaceuticals Corporation 2009) and 
transfer of the drug may occur between various lipoprotein subfractions, and between 
albumin and lipoproteins (Ryan et al., 2010). Cyclosporin is excreted in breast milk, such 
that mothers treated with the compound should not breastfeed (Novartis Pharmaceuticals 
Corporation 2009). 
Cyclosporin is metabolised by the cytochrome P450 (CYP) system, primarily by isozymes 
CYP3A4 and CYP3A5 in the liver and small intestine; the p-glycoprotein pump also has a 
major influence on cyclosporin bioavailability and clearance (Novartis Pharmaceuticals 
Corporation 2009; Ryan et al., 2010).  Cyclosporin is eliminated primarily via the bile. The 
terminal half-life of cyclosporin in plasma has varied from 6–24 hours in various 
populations,(Novartis Pharmaceuticals UK Ltd 2011; Ryan et al., 2010) but in patients with 
psoriasis, the value is probably closer to the lower end of this range (Berth-Jones 2005). 
4. Clinical efficacy 
Cyclosporin is one of the most effective antipsoriatic agents available because of its rapid 
onset of effect and potent immunosuppressive activity against disease flares (Amor et al., 
2010; Ryan et al., 2010). Thus, in patients with severe psoriasis refractory to other agents, 
cyclosporin can produce rapid remission and serve as a useful ‘bridge’ to other treatments 
(Menter et al., 2009). 
The efficacy of cyclosporin is dose-dependent, and times to psoriasis remission are shorter at 
higher doses (Faerber et al., 2001; Timonen et al., 1990). Results from key dose-finding 
studies and meta-analyses for cyclosporin in psoriatic patients are shown in Table 1. In 
patients treated with cyclosporin 1.25–5 mg/kg/day for 10–36 weeks, the PASI70 or PASI75 
response rate (i.e. the proportion of patients with a decrease in Psoriasis Area and Severity 
Index [PASI] score of ≥70% or ≥75% from baseline, or with a decrease to a PASI score of ≤8)  
 
Reference 
Study 
design 
No. of 
patients 
Cyclosporin 
dosage 
(mg/kg/day)
Study 
duration 
Clinical response 
PASI75a 
Global 
disease 
severity 
scoreb 
Christophers 
et al., 1992 
r, df 217 1.25–5 12–36 wks 18–56 - 
Ellis et al., 
1991 
r, db 85 3–7.5 16 wks - 59–77 
Faerber et al., 
2001 
ma 597 1.25–5 10–12 wks 16–50c - 
Timonen et 
al., 1990 
ma 457 1.25–5 3 mos 24–88 - 
a Proportion of patients with a decrease in Psoriasis Area and Severity Index (PASI) score of ≥75% from 
baseline, or with a PASI score ≤8. 
b Percentage decrease in score from baseline. 
c PASI70 response. 
db = double-blind; df = dose-finding; ma = meta-analysis; mos = months; r = randomised; wks = weeks. 
Table 1. Key dose-finding studies and meta-analyses for cyclosporin in psoriatic patients. 
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was 16–88% (Christophers et al., 1992; Faerber et al., 2001; Timonen et al., 1990). Moreover, 
in a 16-week study in 85 patients with severe psoriasis, cyclosporin 3–7.5 mg/kg/day 
reduced global disease severity score by 59–77% (Ellis et al., 1991); however, although major, 
additional efficacy benefits can be obtained at cyclosporin doses >5 mg/kg/day, these 
benefits are offset by increased toxicity (Amor et al., 2010). 
Psychological distress is common in psoriatic patients (Colombo et al., 2010c; Finzi et al., 
2007). A large, observational, follow-up study of more than 1500 psoriatic patients (the 
PSYCHAE study) revealed that methotrexate and topical corticosteroids were associated 
with a significantly increased risk of minor psychological distress, whereas cyclosporin 
significantly reduced such distress, perhaps because of patients’ overall perceptions of 
efficacy and tolerability (Colombo et al., 2010c). This finding has potentially major clinical 
significance, since it outlines the possibility for markedly improved quality of life during 
cyclosporin therapy, but the possibility for detrimental effects on quality of life for certain 
other psoriasis treatments. Additional, comparative investigations are now warranted to 
clearly define the relative effects of cyclosporin and other antipsoriatic agents on quality of 
life (see section 8). 
4.1 Intermittent short-term therapy 
Intermittent short-term therapy for 12–16 weeks is the most widely recommended dosing 
schedule for psoriasis: that is, short courses of cyclosporin are administered until marked 
improvement is evident, whereupon treatment is stopped; if relapse manifests, cyclosporin 
is re-started at the dosage that was earlier effective (Menter et al., 2009). 
 
Fig. 2. Maintained efficacy of intermittent short-term cyclosporin therapy during a large, 1-
year, multicentre, randomised trial in patients with plaque psoriasis (Ho et al., 1999). Values 
shown are the probability of a PASI75 response after 12 weeks’ treatment with cyclosporin 
2.5–5 mg/kg/day. 
In a large, multicentre, randomised trial (the Psoriasis Intermittent Short Courses of Efficacy 
of Sandimmun Neoral® [PISCES] study), 400 patients with plaque psoriasis were initially 
treated with cyclosporin 2.5–5 mg/kg/day until clearance of psoriasis, or for a maximum of 
12 weeks; patients were then randomised to abruptly or gradually discontinue (dosage 
reduction of 1 mg/kg/day each week) cyclosporin therapy. If relapse occurred, patients 
received another course of cyclosporin therapy. After 1 year of follow-up, 117 patients had 
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received 3 cyclosporin courses, and 26 had received 4. After the first treatment course, 
abrupt versus gradual cessation of cyclosporin therapy was associated with a slightly, but 
significantly, shorter time to disease relapse (median 109 vs 113 days; p=0.038). Overall, the 
Kaplan-Meier probability of achieving a ≥75% decrease in disease area after 12 weeks’ 
treatment was 83% after the first cyclosporin course, 76% after the second, 73% after the 
third, and 66% after the fourth [Fig. 2] (Ho et al., 1999). 
In an extension of the PISCES trial, 76 patients were followed-up for a total of 2 years. The 
time in remission during the follow-up period was not significantly different between 
patients stopping cyclosporin therapy abruptly versus gradually (time in remission: 56.2% 
vs 61.8%); overall, the mean proportion of follow-up for which patients received cyclosporin 
was 42.8%. After the first treatment course, the median time to relapse was 115.5 days, but 
this became progressively shorter with an increasing number of cyclosporin courses (Ho et 
al., 2001). 
4.1.1 Prevention of relapse 
The well-designed PREWENT study assessed the efficacy of microemulsion cyclosporin 5 
mg/kg/day, administered each weekend for 24 weeks in a total of 243 adults with chronic 
plaque psoriasis. The primary study endpoint in this multicenter, randomised, double-blind, 
placebo-controlled trial was relapse rate at 24 weeks: thus, 66.9% of cyclosporin-treated 
patients versus 53.2% of placebo recipients (p=0.072) had no worsening of psoriasis (i.e. no 
increase in PASI score to ≥75% of the value recorded before 8–16 weeks’ induction therapy 
with cyclosporin). Although this difference only approached statistical significance, the time 
to first relapse was significantly longer in the cyclosporin than placebo group (p=0.0233), 
and in a post hoc analysis of patients with mild-to-moderate psoriasis, significantly more 
cyclosporin-treated patients than placebo recipients had no worsening of psoriasis (69.9% vs 
46.3%; p=0.011) [Fig. 3] (Colombo et al., 2010a). 
 
Fig. 3. Weekend cyclosporin therapy (5 mg/kg/day) prevents relapse in patients with mild-
to-moderate psoriasis: results from the PREWENT trial (Colombo et al., 2010a). 
p=0.011 
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4.2 Rescue therapy 
Short-term cyclosporin therapy has a rapid onset of effect, and can therefore be 
administered as a rescue or bridging treatment for severe disease flares: that is, until a 
different maintenance therapy is started. As a bridging therapy, cyclosporin can be 
‘dovetailed’ with the new maintenance regimen (e.g. biological therapy, methotrexate) to 
avoid clinical deterioration while the new schedule is taking effect. Cyclosporin can then be 
stopped without a risk of flares, and with a limited risk of adverse effects for only the short 
time that the cyclosporin bridging schedule and the new maintenance regimen are 
dovetailed (Amor et al., 2010). 
Rescue cyclosporin therapy is especially effective in patients with erythrodermic, 
generalised, or suberythrodermic pustular psoriasis; a reducing-dosage strategy is 
employed after starting treatment at 5 mg/kg/day (Menter et al., 2009; Pathirana et al., 
2009). In a study of 33 patients with erythrodermic psoriasis, the initial intervention was 
cyclosporin 4.2 mg/kg/day; after remission, the dosage was reduced by 0.5 mg/kg/day 
every 2 months. At 2–4 months, two-thirds of patients had attained complete remission, and 
marginally more than one-quarter had attained significant clinical improvement (Rosenbach 
et al., 2010). 
4.3 Long-term therapy 
European guidelines recommend that the maximum period of continuous cyclosporin 
therapy in patients with psoriasis should be no more than 2 years (Griffiths et al. 2004; 
Menter et al. 2009; Pathirana et al. 2009). This is primarily because the incidence of renal 
dysfunction and nonmelanoma skin cancer may increase markedly with high doses of 
cyclosporin administered for longer periods (Paul et al. 2003; Ryan et al. 2010). In addition, 
any cyclosporin-related hypertension or renal dysfunction is generally reversible if the dose 
is maintained at ≤5 mg/kg/day and treatment duration at ≤2 years (Ryan et al. 2010). 
Long-term cyclosporin therapy (for up to 2 years or more) maintains its efficacy in most 
psoriatic patients; however, the principal goal of maintenance therapy is not routine 
attainment of clinical remission, but rather attainment of marked clinical improvement with 
the minimum cyclosporin dosage — generally 3–3.5 mg/kg/day (Griffiths et al., 2000). 
Rather surprisingly, given the long-term nature of psoriasis, and in contrast to European 
guidelines, US guidelines stipulate that the duration of cyclosporin therapy should be 
restricted to ≤1 year in psoriatic patients (Amor et al. 2010; Menter et al. 2010). This 
restriction appears rather strange when it is considered that, only with longer-term 
treatment (3–5 years or more) may a substantial proportion of patients experience 
glomerulosclerosis (Menter et al. 2010). 
In a large-scale study involving 285 patients with psoriasis, cyclosporin 1.25–5 mg/kg/day 
administered continuously for 6–30 months reduced mean PASI scores by approximately 
75–94% from baseline, but after cyclosporin cessation, approximately 50% of patients 
experienced a relapse requiring antipsoriatic therapy (Mroweitz et al., 1995). Similarly, in 
another large-scale study (n=181), 86% of patients treated with cyclosporin at a dosage of ~5 
mg/kg/day for 16 weeks had a PASI70 response, and subsequent maintenance therapy with 
cyclosporin 3 mg/kg/day was associated with a significantly longer median time to relapse 
than placebo (p<0.001); at the end of the 24-week maintenance phase, 42% of patients 
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treated with cyclosporin 3 mg/kg/day compared with 84% of placebo recipients had 
relapsed (Shupack et al., 1997). 
A recent, retrospective evaluation of 193 patients with moderate-to-severe psoriasis revealed 
that cyclosporin 1.5–3.1 mg/kg/day (mean dosage) administered for 12–36 (mean 14) 
months reduced mean PASI score from 23.3 to 5.6; the PASI75 response rate was 73.9%. In 
this trial, 83/193 patients (43%) received cyclosporin monotherapy, whereas the remainder 
received polytherapy. Among monotherapy recipients, the physician’s judgement of 
therapeutic success (total clearance of lesions) was 71% of patients, whereas that of clinical 
remission (clearance of lesions with some remaining pigmentation) was 19% of patients. 
Costs to the Italian healthcare system, based on a mean 1.5 cyclosporin courses administered 
over 14 months, were estimated at €2,984 per patient overall; the direct costs of cyclosporin 
acquisition were €2,058 per patient, which are approximately 4½–7 times less than annual 
treatment courses of etanercept and infliximab (Colombo et al., 2010b). To support and 
extend these cost findings, the design and execution of comparative economic evaluations of 
cyclosporin versus biological therapies in patients with moderate-to-severe psoriasis would 
now be particularly pertinent (see section 8). 
In smaller studies, continuous versus intermittent cyclosporin therapy was significantly 
more effective over a 1-year period in 51 patients with chronic plaque psoriasis (PASI75 
response rate: 92% vs 62%, p=0.008), although the mean cumulative annual dose of 
cyclosporin was 1.4-fold greater for continuous therapy (Chaidemenos et al., 2007). 
Furthermore, 60 patients with clearance or near clearance of psoriasis during cyclosporin 
induction therapy (3–7.5 mg/kg/day for 4 months) subsequently received cyclosporin 
maintenance therapy 1.5 or 3 mg/kg/day, or placebo, for up to 4 months (Ellis et al., 1995). 
Mean time to relapse was significantly longer in the higher-dose versus lower-dose 
cyclosporin group (12 vs 9 weeks; p=0.04), and in the higher-dose group versus placebo 
recipients (12 vs 7 weeks; p=0.002). At study completion, markedly fewer patients in the 
higher-dose versus lower-dose versus placebo group had relapsed: 43% vs 79% vs 95% (Ellis 
et al., 1995). 
4.4 Rotational therapy 
Rotational therapy with various systemic agents (e.g. acitretin, fumaric acid esters, 
methotrexate, mycophenolate mofetil) has occasionally been advocated as a means of 
reducing the duration, and any potential toxicity, of cyclosporin therapy (Amor et al., 2010). 
While most patients require additional antipsoriatic therapy after cyclosporin cessation 
(Amor et al., 2010), some patients may have an extended period of remission after 
cyclosporin therapy (Ho et al., 1999, 2001). 
5. Indications/dosage 
In Europe, cyclosporin is indicated for the treatment of severe psoriasis in patients for whom 
conventional therapy is ineffective or inappropriate. After starting treatment with oral 
cyclosporin, psoriatic patients should not be switched to another oral cyclosporin 
formulation without relevant monitoring of plasma cyclosporin levels, creatinine levels, and 
blood pressure; indeed, except for Neoral® soft gelatin capsules and Neoral® oral solution, 
which are bioequivalent, the various oral forms of cyclosporin are not bioequivalent. To 
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avoid any possible confusion among healthcare professionals, and to avoid any potential for 
major fluctuations in cyclosporin bioavailability, cyclosporin should be prescribed by brand 
(Neoral® SPC, 2011). 
To induce remission of psoriasis, the recommended starting dosage of oral cyclosporin is 2.5 
mg/kg actual bodyweight each day, administered in two divided doses; however, when a 
rapid initial response is required, a starting dosage of 5 mg/kg/day can be used (Neoral® 
SPC, 2011). If no improvement is evident after 1 month of 2.5 mg/kg/day, the dosage can be 
gradually increased in 0.5–1 mg/kg increments, at intervals of 2–4 weeks, up to a maximum 
of 5 mg/kg/day (Menter et al., 2009; Neoral® SPC, 2011). Cyclosporin should be stopped if 
the response is inadequate after 6 weeks’ administration of 5 mg/kg/day. However, after an 
initially good response, the cyclosporin dosage can be reduced for maintenance therapy in 
steps of 0.5–1 mg/kg, at intervals of 2 weeks, until the lowest effective dosage level is 
attained (Amor et al., 2010; Neoral® SPC, 2011). Intermittent cyclosporin therapy may be 
appropriate for some psoriatic patients: that is, when an initial satisfactory response has 
been attained, cyclosporin therapy can be stopped and any subsequent relapses treated with 
reintroduction of cyclosporin at the previously effective dosage (Neoral® SPC, 2011). 
Before starting cyclosporin therapy, baseline renal function and blood pressure should be 
measured. Plasma creatinine should be measured every month. If an increase in plasma 
creatinine occurs to ≥30% above baseline, cyclosporin dosage should be reduced by 25–50%, 
even if levels are within the reference range (see section 7.2.2). If such dosage reduction does 
not successfully reduce plasma creatinine within 1 month, cyclosporin should be stopped. 
Similarly, if elevated blood pressure occurs and cannot be controlled by cyclosporin dosage 
reduction, or by intervention with antihypertensive therapy, cyclosporin cessation is 
advocated (Neoral® SPC, 2011). 
6. Combination therapy 
6.1 Topical treatments 
To improve clinical efficacy, cyclosporin has been administered with various topical 
therapies (e.g. corticosteroids, dithranol, vitamin D3 analogues [e.g. calcipotriol]) (Amor et 
al., 2010). However, data supporting such strategies stem mainly from small-scale, 
uncontrolled studies (Gottlieb et al., 1995; Griffiths et al., 1989). For example, in 12 
psoriatic patients treated with cyclosporin 5 mg/kg/day for up to 18 weeks, and who 
applied topical dithranol to plaques on half of their bodies, improved clinical efficacy (e.g. 
significantly reduced severity index) was noted for combination therapy in 58% of 
patients (Gottlieb et al., 1995). In 13 patients with severe persistent psoriasis, cyclosporin 
1–4 mg/kg/day was administered for 12–25 months, and an 81% decrease was noted in 
mean PASI score; 85% of the patients had received topical corticosteroid therapy after the 
first 3 months of cyclosporin (Griffiths et al., 1989). A larger randomised, double-blind, 
placebo-controlled trial in 69 cyclosporin-treated (2 mg/kg/day) patients with severe 
chronic plaque psoriasis revealed clinical improvement in a significantly greater 
proportion of patients who used concomitant calcipotriol 50 µg/g ointment versus 
vehicle: 50% vs 12% of patients (p=0.0019) had complete clearing of psoriasis or a ≥90% 
improvement in PASI score (Grossman et al., 1994). 
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6.2 Systemic treatments 
Combination schedules of cyclosporin plus other systemic antipsoriatic agents (e.g. fumaric 
acid esters, methotrexate, mycophenolate mofetil) have been used in patients with severe 
psoriasis to facilitate cyclosporin dosage reduction and to reduce the risk of potential 
adverse effects (Amor et al., 2010). For instance, in small-scale, uncontrolled trials: 
 Cyclosporin plus methotrexate was administered for a mean of up to about 3½ years in 
19 patients with severe recalcitrant psoriasis, and the combination schedule produced 
good control of psoriasis using lower doses of each agent than would have been used 
for monotherapy; however, 6 patients developed renal impairment, which normalised 
(n=3), or which improved but did not normalise (n=3), after cyclosporin dosage 
reduction (Clark et al., 1999). 
 Cyclosporin 2.5 mg/kg/day plus mycophenolate mofetil 3 g/day led to moderate or 
good clinical improvement over 3–11 months’ follow-up in 78% of patients with severe 
recalcitrant psoriasis (Ameen et al., 2001). 
Interestingly, in a retrospective assessment of 193 cyclosporin-treated patients with 
moderate-to-severe plaque psoriasis, 110 patients (57%) had received concurrent therapy 
with systemic methotrexate or retinoids, or topical and/or phototherapy. In the physician’s 
judgement, a clinical response (therapeutic success or clinical remission) occurred in 80% of 
combination therapy recipients (Colombo et al., 2010b). Cyclosporin was also investigated in 
combination with phototherapy. In a study comparing sequential cyclosporin and narrow-
band (NB) UVB phototherapy versus NB UVB phototherapy alone in patients with severe 
psoriasis, both treatments were effective and well tolerated, but the sequential therapy 
showed a greater efficacy on lesions of UV-shielded body areas and on itching (Calzavara-
Pinton et al., 2005). The increased efficacy of the sequential therapy allowed for the 
reduction of NB UVB dosage and exposure. Nonetheless, it should be remembered that 
psoriatic patients previously treated with psoralen and ultraviolet A (PUVA), and to a lesser 
extent UVB, have increased risks of skin malignancies during cyclosporin therapy. Psoriatic 
patients receiving cyclosporin should not receive concomitant PUVA or UVB therapy 
(Neoral® Prescribing Information, 2009). 
7. Side effects 
Side effects, such as hypertension and renal impairment, may be associated with continuous 
cyclosporin therapy and appear related to treatment duration and dose (Colombo et al., 
2010a). Generally, such side effects are reversible after cyclosporin discontinuation, although 
rarely chronic renal impairment and structural abnormalities in the kidneys may persist and 
be irreversible (Ryan et al., 2010). To minimise the risk of nephrotoxicity, the most widely 
recommended cyclosporin regimen in psoriasis is a short-term schedule of 2.5–5.0 
mg/kg/day for 12–16 weeks (see section 5); this short course is repeated if subsequent 
disease flares occur (Amor et al., 2010; Griffiths et al., 2004). Adhering to present guidelines 
about appropriate dosage and monitoring protocols for cyclosporin use in psoriatic patients 
will substantially reduce the risk of side effects (Griffiths et al., 2004; Menter et al., 2009; 
Pathirana et al., 2009). 
Although the mechanisms for many cyclosporin-related adverse effects have not been 
clearly defined, immunophilin inhibition (especially inhibition of immunophilins involved 
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in the regulation of mitochondrial ion channels) and mitochondrial dysfunction may have 
significant pathogenetic roles (Ryan et al., 2010). Adverse effects reported in large-scale 
randomised controlled trials and meta-analyses of short-term or longer-term cyclosporin 
therapy in psoriatic patients are documented in Table 2. As can be seen, in short-term  
 
Study features/AEsa
Short-term 
cyclosporin therapy
Longer-term cyclosporin therapy 
Ellis et 
al., 1991
Faerber et 
al., 2001 
Christophers 
et al., 1992 
Krupp & 
Monka, 
1990 
Mrowietz 
et al., 1995 
Shupack 
et al., 
1997 
No. of patients 85 579 285 631 88 181 
Dosage 
(mg/kg/day) 
3–7.5 1.25–5 1.25–5 1.25–5 1.25–5 1.5–6 
Duration 16 wks 10–12 wks 12–36 wks 
12 wks–16 
mos 
6–30 mos 40 wks 
AEs requiring 
discontinuation 
4.7 4.1 1.6–3.2 5.9 5.7 7.0–11.0 
Renal dysfunction 18e ≤8 1–13 na 5 17–43 
Hypertension na 5–14 11–26 na 8 9f 
GI side effects 28–55 3–8 4–5 12 22 12f 
Headache 20–53 2–4 ≤5 6 3 30f 
Tremor 4–25 na ≤2 1 2 na 
Paraesthesias 16–40 na ≤1 11 na 18f 
Hypertrichosis 24–27 ≤5 1–2 7 2 17f 
Hypercholesterolaem
ia 
na na 12–25 na na na 
Hypertriglyceridaem
ia 
na na 20–53 na 13 na 
CV symptomsb 5–8 na na na na na 
CNS symptomsc 7–25 1–6 na na na na 
Fatigue 12–20 ≤4 1–2 3 na 11f 
Influenza-like 
symptoms 
5–20 na na na 9 na 
Infectiond 20–27 na 2 na na na 
Gum hypertrophy 8–15 na 1–2 4 2 na 
a Percentage of patients, unless otherwise stated. 
b Chest pain, premature ventricular contraction, tachycardia. 
c Anxiety, depression, dizziness, insomnia, nervousness, syncope, visual changes, transient ischaemic 
attack. 
d Non-influenza-like viral, bacterial, and fungal infections. 
e ≥15% decrease in glomerular filtration rate. 
f During 16-wk induction phase (5 mg/kg/day). 
AE = adverse effect; CNS = central nervous system; CV = cardiovascular; GI = gastrointestinal; mos = 
months; na = not available; wks = weeks. 
Table 2. Principal side effects reported in large-scale, well-designed clinical trials and meta-
analyses of cyclosporin therapy in patients with psoriasis. 
www.intechopen.com
 
Psoriasis 
 
298 
studies of up to 16 weeks’ duration, about 4–5% of cyclosporin-treated patients had adverse 
effects requiring treatment discontinuation (Ellis et al., 1991; Faerber et al., 2001). In a meta-
analysis of 3 major German studies in approximately 600 patients with severe plaque 
psoriasis, and across the dosage range 1.25–5.0 mg/kg/day, the principal side effects were 
hypertension (5–14% of patients), renal dysfunction (≤8%), and gastrointestinal problems (3–
8%); increased plasma creatinine levels required intervention in only 3.4% of the total 756 
cyclosporin treatment cycles (Faerber et al., 2001). 
In longer-term studies of up to 30 months’ duration, but across the same dosage range 1.25–
6 mg/kg/day, up to 11% of patients discontinued cyclosporin because of adverse effects; 
hypertension occurred in 8–26% of patients, gastrointestinal problems in 1–22%, and renal 
dysfunction in 1–43%. Lipid disorders also manifested: hypercholesterolaemia in 12–25% of 
patients, and hypertriglyceridaemia in 13–53% of patients (Christophers et al., 1992; Krupp 
& Monika, 1990; Mrowietz et al., 1995; Shupack et al., 1997). 
Interestingly, in a recent, well-designed evaluation of relapse rates in patients with chronic 
plaque psoriasis who had achieved clinical remission after continuous cyclosporin therapy, 
243 patients were randomised to 24 weeks of weekend cyclosporin microemulsion therapy 5 
mg/kg/day or placebo (the Psoriasis Relapse Evaluation with Week-End Neoral Treatment 
[PREWENT] study) (Colombo et al., 2010a). In this investigation in a ‘real-life’ clinical 
setting, rather than in a group of carefully selected psoriatic patients, cyclosporin was well 
tolerated: no significant difference was evident in the incidence of adverse events between 
cyclosporin and placebo recipients (38.4% vs 21.5%). Only one patient (a cyclosporin 
recipient) had a serious adverse event (breast mass), but this was considered unrelated to 
study treatment. Furthermore, at no time during the study were mean plasma creatinine 
levels, or systolic and diastolic blood pressure values, different between the two groups; the 
incidence of plasma creatinine levels >30% above baseline was similar in the two groups 
(5.0% vs 3.8% of patients) (Colombo et al., 2010a) 
In a retrospective assessment of 193 patients with moderate-to-severe psoriasis who had 
received a mean cyclosporin dosage of 1.5–3.1 mg/kg/day for 14 months, 83 patients (43%) 
received cyclosporin as monotherapy (Colombo et al., 2010b). Altogether, marginally more 
than one-third of patients experienced at least one adverse event. The most frequent events 
were hypertension (17.6% of patients), hypercholesterolaemia (14.0%), raised plasma 
creatinine level to >30% above baseline (6.7%), and gastrointestinal symptoms (6.2%). The 
clinician’s assessment of cyclosporin tolerability was ‘very good’ or ‘good’ in 90% of cases 
(Colombo et al., 2010b). 
Overall, the possibilities of cyclosporin-induced hypertension and renal dysfunction are 
perhaps the major tolerability concern among prescribers, and might explain a certain 
degree of cyclosporin ‘under-utilisation’ by dermatologists (Ryan et al., 2010). These two 
side effects are discussed in more detail below, whereas other potential tolerability issues 
are addressed relatively briefly. 
7.1 Hypertension 
The incidence of new-onset hypertension during cyclosporin administration to psoriatic 
patients has varied somewhat in short-term studies (5-14% of patients) and longer-term 
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trials (8–26%; Table 2). Such hypertension is generally reversible after the cyclosporin 
dosage is reduced, or after antihypertensive medications are added (Ho et al., 1999; Ryan et 
al., 2010). Importantly, besides specific drug therapy, psoriasis per se may contribute to an 
increased risk of hypertension, since psoriatic patients have increased incidences of obesity 
and metabolic syndrome (Gelfand et al., 2006). 
Pooled data from 10 studies involving 563 patients with severe psoriasis revealed an 
overall incidence of new-onset hypertension of 10.6% during cyclosporin therapy (Feutren 
et al., 1990). However, the occurrence of hypertension was not dose-related (10.0% of 
patients at 2.5 mg/kg/day; 11.9% at 5.0 mg/kg/day) (Feutren et al., 1990), and this 
finding agrees with that of several randomised trials (Ryan et al., 2010). The implication, 
therefore, is that a subset of psoriatic patients exists with heightened sensitivity to 
cyclosporin, and enhanced susceptibility to hypertension, even at low cyclosporin doses 
(Ryan et al., 2010). Thus, cyclosporin-induced hypertension may best be managed with 
antihypertensive therapy rather than with a reduced cyclosporin dosage (Feutren et al., 
1990; Ryan et al., 2010). 
7.1.1 Management of hypertension 
Psoriatic patients have an increased risk of cardiovascular morbidity and mortality (Gelfand 
et al., 2006). Regular blood pressure monitoring (e.g. weekly self-monitoring) is therefore 
important in cyclosporin-treated patients with psoriasis. If hypertension occurs, current 
guidelines advocate a cyclosporin dosage reduction of 25–50%, or commencement of 
antihypertensive therapy (Griffiths et al., 2004; Pathirana et al., 2009). Dihydropyridine 
calcium-channel blockers (e.g. amlodipine, isradipine) are generally the interventions of 
choice, since they confer some degree of nephroprotection (Ryan et al., 2010). 
7.2 Renal dysfunction 
Though renal dysfuntion is recognized as a cyclosporin-related side effect, the real impact of 
cyclosporin on kidney function may need to be reassessed. The experience in transplant 
patients, particularly in kidney transplant recipients where cyclosporin is used at higher 
doses in life-long regimens shows, that these regimens are well tolerated (Cho & Terasaki, 
1988; Opelz, 1994). An Italian study conducted in 573 kidney transplant recipients showed 
that creatinine plasma levels remain constant and around 1.5 mg/dl over 15 years after the 
intervention, a clear indication of stable kidney function ( Sandrini, data presented at SIN 
2003 Bologna).  
When renal dysfunction persists during cyclosporin therapy, it is usually related to higher 
doses (>5 mg/kg/day) or extended treatment (>2 years), and both of these factors may lead 
to structural renal damage. Renal dysfunction may also comprise functional impairment (i.e. 
vascular or tubular dysfunction), which may be evident soon after starting treatment. The 
consequences of vascular dysfunction are reduced glomerular filtration rate and renal blood 
flow, and reduced creatinine clearance, whereas the consequences of tubular dysfunction 
may include hypomagnesaemia, reduced plasma bicarbonate levels, hyperuricaemia, and 
hyperkalaemia. Acute functional impairment is generally reversible when cyclosporin 
treatment is discontinued; thus, the risk of renal toxicity is minimised when intermittent 
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cyclosporin therapy is prescribed in psoriasis, since such therapy is associated with 
normalisation of renal function between treatment courses (Ryan et al., 2010). 
Besides raised plasma creatinine levels, other predictors of cyclosporin-related 
nephropathy include advanced age, obesity, new-onset or pre-existing hypertension or 
renal disorders, and other nephrotoxic treatments. Altogether, as relatively low 
cyclosporin dosages are now used in psoriasis, tubulopathic changes are rare and 
reversible (Ryan et al., 2010). 
7.2.1 Management of renal dysfunction 
If plasma creatinine levels are ≥30% above baseline on two consecutive occasions, 2 weeks 
apart, the cyclosporin dosage should be reduced by 25–50% for at least 4 weeks; this applies 
even if creatinine values are within the normal reference range (Griffiths et al., 2004; Menter 
et al., 2009; Pathirana et al., 2009). After 4 weeks of reduced-dosage treatment, if plasma 
creatinine levels remain elevated, cyclosporin should be discontinued (Neoral® SPC, 2011). 
As a preventive measure against renal dysfunction, it is recommended that psoriatic 
patients receiving long-term cyclosporin therapy should have glomerular filtration rate 
measured at least once each year (Griffiths et al., 2004; Pathirana et al., 2009). Guidelines 
from the European Association of Dermatology and Venereology and from the British 
Association of Dermatology stipulate that the maximum period of continuous cyclosporin 
therapy in psoriatic patients should not exceed 2 years (Griffiths et al., 2004; Menter et al., 
2009; Pathirana et al., 2009). As a comparison, it should be reminded that in graft recipients, 
life-long regimens with higher cyclosporin doses are routinely used in clinical practice and 
have proved well tolerated after many years of use. 
Generally, if the cyclosporin dosage is ≤5 mg/kg/day, and if patients are closely monitored 
so that plasma creatinine levels remain ≤30% above baseline, any renal side effects will be 
wholly reversible after cyclosporin treatment is stopped (Ryan et al., 2010). 
7.3 Central nervous system effects 
Headache may occur in up to 53% of cyclosporin-treated patients with psoriasis, 
paraesthesias in up to 40%, and tremor in up to 25% (Table 2). The latter two effects 
generally occur during the first few weeks of cyclosporin administration and dissipate after 
a decrease in cyclosporin dosage; hypomagnesaemia has been postulated as a cause of these 
effects (Ryan et al., 2010). 
Seizures have been reported rarely during cyclosporin therapy, but cyclosporin does have 
the potential to reduce seizure threshold in epileptic patients; the seizure risk is increased in 
patients taking concurrent, high-dose corticosteroid therapy. Furthermore, patients taking 
antiepileptic drugs may have reduced circulating cyclosporin levels because of increased 
metabolism by the cytochrome P450 system (Ryan et al., 2010). 
7.4 Gastrointestinal effects 
The rates of cyclosporin-induced gastrointestinal side effects (e.g. abdominal pain, 
diarrhoea, dyspepsia, nausea, and vomiting) vary markedly: however, a meta-analysis 
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involving 631 psoriatic patients reveals rates of 2.3%, 2.0%, 2.0%, 3.8%, and 1.1%, 
respectively (Krupp & Monka, 1990). 
7.5 Gingival hyperplasia 
Gingival hyperplasia may occur in up to 30% of patients taking cyclosporin and is often 
linked with poor oral hygiene (Ryan et al., 2010). Thanks to increased oral health awareness, 
improved oral hygiene, and better public health service this condition occurs rarely in 
developed countries. If it occurs, this side effect usually manifests within the first 3–6 
months of treatment. 
7.6 Hyperlipidaemia 
Hypertriglyceridaemia (>750 mg/dL) occurs in approximately 15% of cyclosporin-treated 
patients, and hypercholesterolaemia in <3% (Neoral® Prescribing Information, 2011). 
Importantly, hyperlipidaemia normalizes when cyclosporin therapy is stopped (Shupack 
et al., 1997). 
Severe psoriasis is associated with increased cardiovascular morbidity and mortality (see 
section 7.1.1); thus, hyperlipidaemia should be actively managed in cyclosporin-treated 
patients with psoriasis. If cyclosporin therapy is continued, the initial intervention is a lipid-
lowering diet. If this is unsuccessful, the cyclosporin dosage should be reduced, or treatment 
with a lipid-lowering agent started. Fluvastatin was shown to be well tolerated in 
association with cyclosporin (Holdaas et al., 1995; Launay-Vacher 2005). In general, 
however, statins should be used with caution because of the risk, albeit very low, of 
rhabdomyolysis, as reported in a few cases of transplanted patients treated with cyclosporin 
and lovastatin or simvastatin (Ryan et al., 2010; Corpier et al., 1988).  
7.7 Hypertrichosis 
In large-scale clinical trials and meta-analyses in cyclosporin-treated patients with psoriasis, 
the incidence of hypertrichosis has varied widely from 1–27% (Table 2); the cause of this 
side effect is unclear, but it is  unlikely to be an altered endocrine status (Ryan et al., 2010). 
7.8 Infections 
Cyclosporin-induced infections occur rarely, and are rarely severe; controlled studies in 
psoriasis report no difference in the incidence of infections between cyclosporin and placebo 
recipients. Moreover, an overview of 20 years’ safety data for cyclosporin in dermatology 
patients revealed no increases in the risks of opportunistic infections or tuberculosis 
reactivation (Ryan et al., 2010). 
7.9 Malignancies 
7.9.1 Lymphomas 
B- and T-cell lymphomas have rarely been reported in cyclosporin-treated patients with 
psoriasis (Ryan et al., 2010). For instance, 2/842 patients (0.2%) developed these lymphomas 
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in a large-scale trial (Krupp & Monka, 1990), whereas no increase in the incidence of 
lymphomas was noted in another large-scale trial (Paul et al., 2003). Significantly, psoriasis 
itself leads to chronic immunological overactivation, and to greater risks of lymphoma and 
other malignancies than in the general population (Ryan et al., 2010).  
7.9.2 Nonmelanoma skin cancers 
In 1252 patients with severe psoriasis, low-dosage cyclosporin (2.7–3.1 mg/kg/day) was 
associated with a 6-fold increase in cutaneous squamous cell carcinomas after up to 5 
years’ follow-up. The greatest risks of these nonmelanoma skin cancers were in patients 
treated with cyclosporin for >2 years, in patients previously exposed to PUVA, and in 
patients exposed to other immunosuppressants or methotrexate (Paul et al., 2003). In 
another large-scale study, 6/842 psoriatic patients (0.7%) developed premalignant or 
malignant skin lesions during cyclosporin therapy, but nearly all of these patients had 
received previous treatment with PUVA, ultraviolet B, or methotrexate (Krupp & Monka, 
1990). 
The current recommendation is that if phototherapy is considered in psoriatic patients, 
narrowband ultraviolet B should be the first choice; cyclosporin can then be reserved for 
future therapy, if necessary (Griffiths et al., 2004; Pathirana et al., 2009). Cyclosporin 
should not be used together with phototherapy, or immediately before or after PUVA (see 
section 5); in patients with a high total dose of PUVA, or with a history of squamous cell 
carcinoma or melanoma, cyclosporin should be avoided (Griffiths et al., 2004; Pathirana et 
al., 2009). 
7.9.3 Solid organ tumours 
Numerous case reports exist of solid organ tumours developing during cyclosporin 
treatment in dermatology patients (Ryan et al., 2010). However, no increase in the incidence 
of solid organ tumours was noted in a study of 1252 psoriatic patients treated with 
cyclosporin (Paul et al., 2003), and although another large-scale study reported solid organ 
tumours in 5/842 patients (0.6%), the lead investigator considered any relationship between 
these tumours and cyclosporin to be unlikely (Krupp & Monka, 1990). Large case-control 
studies suggest that cyclosporin plus other immunosuppressive therapies may actually have 
immunoprotective effects against, and reduce the risks of, some tumour types (e.g. breast 
and rectal cancers) (Ryan et al., 2010). 
7.10 Other side effects 
Fatigue and influenza-like symptoms may occur in up to 20% of cyclosporin-treated patients 
(Table 2), and joint pain and muscle aches are also frequently reported (10–40% of patients) 
(Pathirana et al., 2009). 
Hyperbilirubinaemia manifests in up to one-third of cyclosporin recipients (Pathirana et al., 
2009), but this effect is usually dose-related, and does not require further investigation if 
other liver function abnormalities are absent (Ryan et al., 2010). Transaminase elevations 
may also occur in up to one-third of cyclosporin-treated patients. If plasma bilirubin or 
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transaminase levels are >2 x the upper limit of normal, the cyclosporin dosage should be 
reduced by 25% (Pathirana et al., 2009). 
8. Drug interactions 
Several drug interactions have been documented for cyclosporin, which is extensively 
metabolised by the CYP 3A system in the liver and small intestine. Some of the key 
interactions include the following: (Novartis Pharmaceuticals Corporation 2009; Ryan et 
al., 2010) 
 Erythromycin should be used with caution in cyclosporin-treated patients with infected 
eczema, since the former compound can increase cyclosporin toxicity. 
 Grapefruit juice inhibits cyclosporin metabolism and should be avoided in cyclosporin 
recipients. 
 Heavy alcohol ingestion should be avoided, as it can increase cyclosporin levels. 
 Nephrotoxic drugs, including aminoglycosides, ciprofloxacin, clotrimazole, fibrates, 
and nonsteroidal anti-inflammatory drugs (NSAIDs), should not be administered, if at 
all possible, to cyclosporin-treated patients. NSAIDs, especially in dehydrated patients, 
are likely to potentiate the deleterious effect of cyclosporin on renal function, and 
importantly, intermittent NSAID use is often not disclosed by patients. 
 Cyclosporin may restrict the metabolism of many drugs (e.g. diclofenac, digoxin, 
methotrexate, prednisolone, repaglinide, simvastatin), thus increasing plasma levels 
and toxicity. 
 Cyclosporin should not be used concomitantly with potassium-sparing diuretics 
because of the risk of hyperkalaemia, and care should also be exercised if cyclosporin is 
administered concurrently with potassium-sparing drugs such as angiotensin-
converting enzyme inhibitors or angiotensin II receptor antagonists. 
9. Conclusions 
Cyclosporin was first approved for the treatment of severe psoriasis in the 1990s, and 
indeed, it is one of the most effective antipsoriatic agents available because of its fast onset 
of action and potent immunosuppressive activity. Besides psoriasis, other dermatological 
disorders — most notably, pyoderma gangrenosum and refractory chronic idiopathic 
urticaria — have seen substantial off-label cyclosporin use in recent years. Nonetheless, 
concerns remain among some dermatologists about the safety of cyclosporin, even though a 
growing evidence base exists of a favourable benefit : risk profile for the compound, 
especially in the management of psoriasis, psoriatic arthritis, and atopic dermatitis. 
Perhaps the most frequent safety concerns, and those potentially explaining under-
utilisation of cyclosporin by some dermatologists, are hypertension and renal impairment. 
However, it should be remembered that psoriasis itself is associated with increased 
cardiovascular morbidity, and any new hypertension emerging during cyclosporin therapy 
can be managed effectively by dosage reduction and/or antihypertensive therapy. 
Moreover, persistent renal dysfunction during cyclosporin therapy is usually associated 
with dosages >5 mg/kg/day, or treatment periods of >2 years; usually, if the dosage is kept 
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at ≤5 mg/kg/day, and if renal function is monitored closely so that plasma creatinine levels 
remain ≤30% above baseline, any renal side effects occurring during cyclosporin therapy 
will be reversible when treatment is stopped. 
Safety concerns may also exist about possible malignancies during cyclosporin 
administration. Again, however, it should be emphasised that the disease itself leads to 
long-term immunological overstimulation, such that psoriatic patients have greater risks of 
lymphoma and other malignancies compared to the general population. Any risk of 
nonmelanoma skin cancer during cyclosporin administration appears to be minimised if the 
duration of continuous therapy is kept to ≤2 years, and if PUVA is avoided; and some 
studies suggest that cyclosporin plus other immunosuppressant therapy may actually 
reduce the risks of some cancers (e.g. breast, rectal). 
Additional well-designed assessments of various cyclosporin schedules are now warranted 
in the treatment of psoriasis. Such assessments should include: 
 Comparative studies — i.e. vs traditional treatments (e.g. methotrexate) and/or newer 
agents (e.g. etanercept, infliximab). 
 Measures of economic and quality-of-life endpoints, such that relative cost-utility and 
cost-effectiveness, and important considerations such as effects on psychological 
distress, can be quantified and clarified. 
 Careful evaluation of the clinical potential of specific combination therapy schedules 
(e.g. cyclosporin plus topical calcipotriol; low-dose cyclosporin plus mycophenolate 
mofetil, with a possible view to the development of a fixed-dose combination ‘pill’ with 
enhanced tolerability). This is particularly pertinent given that most studies of 
combination therapy to date have been small-scale, uncontrolled evaluations. 
 Long-term studies  of ≥2 years’ duration. 
In summary, the immunosuppressive properties of cyclosporin in the transplant and non-
transplant settings have been widely recognised for approximately 3½ decades. As such, 
there is much clinical knowledge and experience of cyclosporin use in non-dermatological 
settings, but in the dermatological arena, clinical experience is ‘catching up’. Cyclosporin 
has now been used in the treatment of psoriasis for almost 15 years, and with the relatively 
low doses used, dermatologists appear to be moving beyond any potential safety concerns 
about the compound, and are increasingly embracing the established antipsoriatic efficacy 
of the drug. As further clinical, economic, and quality-of-life data accrue from well-
conducted clinical trials of cyclosporin monotherapy and combination therapy schedules, 
dermatologists, policy makers, and patients are likely to gain even more confidence in the 
favourable efficacy and tolerability profiles of cyclosporin in the treatment of psoriasis and 
other dermatological disorders. 
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